92 results on '"Zielinski C"'
Search Results
2. Reply to the letter to the editor ‘Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?’ by Del Paggio
3. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
4. Decreased body mass index is associated with impaired survival in lung cancer patients with brain metastases: A retrospective analysis of 624 patients
5. ESMO-Magnitude of Clinical Benefit Scale version 1.1
6. Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment
7. Reply to the letter to the editor ‘The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice’ by Hartmann and the letter ‘Comment on ESMO Magnitude of Clinical Benefit Scale’ by Muhonen et al.
8. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
9. A network meta-analysis comparing the efficacy and safety of anticoagulants for the treatment of venous thromboembolism in cancer patients: OR260
10. Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality
11. Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients – results from the Vienna Cancer And Thrombosis Study (CATS)
12. Delivering precision medicine in oncology today and in future—the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO)
13. Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients
14. Present and future breast cancer management—bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry
15. The landscape of medical oncology in Europe by 2020†
16. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24)
17. Presence of varicose veins in cancer patients increases the risk for occurrence of venous thromboembolism
18. Biomarkers predictive of venous thromboembolism in patients with high grade gliomas: PB 3.60–2
19. Association of interleukins with venous thromboembolism and mortality in cancer patients: PA 1.16–5
20. Association of mean platelet volume with cancer-associated venous thromboembolism: results from the vienna cancer and thrombosis study (CATS): OC 31.1
21. FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study
22. Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer
23. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents
24. Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients
25. Urokinase-type plasminogen activator receptor (uPAR) regulates angiogenesis via interaction with low density lipoprotein receptor-(LDLR-) like proteins: DC.01
26. Third CECOG consensus on the systemic treatment of non-small-cell lung cancer
27. HER- Inhibition: V942
28. Extracellular matrix remodeling and stromal cell-derived tumor promotion in the bone marrow reflect the progression of MGUS to multiple myeloma - a proteome profiling study: V110
29. Urokinase receptor (UPAR) mediated integrin redistribution represents a central mechanism for growth factor induced endothelial cell migration: O-TH-120
30. Urokinase plasminogen activator receptor (UPAR) regulates angiogenesis via direct interaction with low density lipoprotein receptor (LDLR-) like protein in endothelial cells: O-WE-044
31. Microparticle-associated tissue factor activity in pancreatic- and brain cancer patients: impact on thrombosis risk and survival: O-WE-037
32. Complete neurologic and cognitive recovery after plasmapheresis in a patient with chronic inflammatory polyneuropathy after allogeneic bone marrow transplantation: P711
33. Undifferentiated naive and differentiated effector memory T-lymphocytes in chronic graft-versus-host disease: results of a prospective study: P448
34. Excess of BAFF and distortion of B-cell homeostasis in patients with newly diagnosed bronchiolitis obliterans syndrome associated with chronic graft-versus-host disease: 0152
35. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis
36. Thrombosis risk and survival in cancer patients with elevated C-reactive protein
37. Reply to Capecitabine dosing is not yet optimized for breast cancer
38. Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?
39. Bevacizumab as first-line therapy for advanced breast cancer: V57
40. Metastatic breast cancer: V16
41. Growth factor induced endothelial cell migration requires urokinase receptor (uPAR)-dependent integrin redistribution: O5B-5
42. uPAR/LDLR interaction: a novel target for efficient endothelial cell migration: O5B-4
43. Verschiebungen innerhalb der B-Zell-Homeostase bei chronischer Graft-versus-Host-Erkrankung der Lunge: 057
44. Patienten mit chronischer Graftversus-Host-Erkrankung und Dysgammaglobulinämie unterscheiden sich in ihren zirkulierenden B-Zell-Subpopulationen: 018
45. Trastuzumab treatment in patients with breast cancer and metastatic CNS disease
46. Reply to Third consensus on medical treatment of metastatic breast cancer
47. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)
48. Third consensus on medical treatment of metastatic breast cancer
49. Predicting for benefit from trastuzumab in multiple lines: V49
50. Absence of efficacy of thalidomide monotherapy in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.